WORK to Save Lives Act

H.R. 7479, the Workplace Overdose Reversal Kits to Save Lives Act, was introduced on February 10, 2026, and referred to the House Committee on Education and Workforce. The bill's sponsor is Rep. Watson Coleman (D-NJ-12) with 15 cosponsors. It is currently in an early stage with no hearings or markup scheduled on the House side, though the companion bill S. 3812 has had hearings in the Senate HELP Committee. The bill mandates that the Secretary of Labor, through OSHA, issue non-mandatory guidance for private employers on acquiring and maintaining opioid overdose reversal medication (e.g., naloxone) and offering voluntary annual employee training. For federal agencies, compliance would be mandatory via regulation. There is no authorized or appropriated funding in the bill — it only directs regulatory action. Therefore, no direct revenue stream is created for any company. Manufacturers of naloxone or overdose reversal medications (e.g., Emergent BioSolutions $EBS or Opiant Pharmaceuticals, now part of Indivior $INDV) could see a minor uptick in demand if adoption increases, but the non-mandatory nature for private employers means adoption is uncertain and likely low. For naloxone kits and related training, major suppliers include Emergent BioSolutions ($EBS) for Narcan nasal spray and generic manufacturers, but the bulk of sales are already driven by standing orders and state mandates, not this bill. Any potential revenue is speculative and not material at this stage. The legislation's primary effect would be on federal agencies, which already have similar mandates in many cases. No tickers meet the confidence gate for a causal chain because the mechanism is non-mandatory for 99% of the workforce and zero funding is involved. The legislative path requires committee markup, House floor passage, Senate reconciliation with S. 3812, and presidential signature — all before December 2026. Probability of enactment in the current session is low given the divided 119th Congress and early-stage status.